US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US5605889A
(en)
|
1994-04-29 |
1997-02-25 |
Pfizer Inc. |
Method of administering azithromycin
|
DE69524214T3
(de)
*
|
1994-05-06 |
2008-05-15 |
Pfizer Inc. |
Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
US6262115B1
(en)
*
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
US6548084B2
(en)
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
US6645988B2
(en)
*
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6699885B2
(en)
*
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6489346B1
(en)
*
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
HRP970493A2
(en)
*
|
1996-09-23 |
1998-08-31 |
Wienman E. Phlips |
Oral delayed immediate release medical formulation and method for preparing the same
|
AU1075997A
(en)
*
|
1996-11-15 |
1998-06-10 |
Procter & Gamble Company, The |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US20040028735A1
(en)
*
|
1997-11-14 |
2004-02-12 |
Unchalee Kositprapa |
Pharmaceutical formulation
|
US6306642B1
(en)
*
|
1997-11-24 |
2001-10-23 |
Quidel Corporation |
Enzyme substrate delivery and product registration in one step enzyme immunoassays
|
MEP30008A
(en)
*
|
1998-03-26 |
2010-10-10 |
Astellas Pharma Inc |
Sustained release preparations
|
EP1449524A1
(fr)
*
|
1998-06-03 |
2004-08-25 |
ALZA Corporation |
Methodes et dispositifs servant à maintenir un effet therapeutique prolongé
|
DE19850445A1
(de)
*
|
1998-11-02 |
2000-05-04 |
Falk Pharma Gmbh |
Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
ATE404178T1
(de)
*
|
1999-02-10 |
2008-08-15 |
Pfizer Prod Inc |
Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
|
US6878386B1
(en)
*
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
BR0013719A
(pt)
*
|
1999-09-02 |
2002-07-23 |
Nostrum Pharmaceuticals Inc |
Dosagem oral de liberaçâo controlada, apropriada para administração oral
|
TR200201646T2
(tr)
*
|
1999-12-23 |
2002-11-21 |
Pfizer Products Inc. |
Hidrojel tahrikli ilaç dozaj biçimi
|
JP2003518487A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動型積層薬物製剤
|
IL141438A0
(en)
*
|
2000-02-23 |
2002-03-10 |
Pfizer Prod Inc |
Method of increasing the bioavailability and tissue penetration of azithromycin
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US20050175959A1
(en)
*
|
2000-03-14 |
2005-08-11 |
Coll Partners Ltd. |
System for the controlled delivery of an active material to a dental site
|
IL135061A0
(en)
*
|
2000-03-14 |
2001-05-20 |
Ahron Jodaikin |
Strategic targeted fluoridation and chemical treatment of teeth
|
US6569152B2
(en)
|
2000-03-21 |
2003-05-27 |
Farrington Pharmaceuticals, Llc |
Sustained release delivery systems for solutes
|
FR2811571B1
(fr)
*
|
2000-07-11 |
2002-10-11 |
Flamel Tech Sa |
Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
BR0113626A
(pt)
|
2000-08-30 |
2003-06-17 |
Pfizer Prod Inc |
Formulações de liberação sustentada para secretores de hormÈnio do crescimento
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
GB0025208D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Euro Celtique Sa |
Delayed release pharmaceutical formulations
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
FR2821745B1
(fr)
*
|
2001-03-09 |
2004-07-02 |
Ethypharm Lab Prod Ethiques |
Granules et granules enrobes au gout masque
|
AU2002248792B2
(en)
*
|
2001-04-18 |
2006-09-21 |
Nostrum Pharmaceuticals Inc. |
A novel coating for a sustained release pharmaceutical composition
|
HRP20010301A2
(en)
*
|
2001-04-27 |
2001-12-31 |
Pliva D D |
New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
|
EP1671979B1
(fr)
|
2001-05-22 |
2008-08-13 |
Pfizer Products Inc. |
Nouvelle forme cristalline de l'azithromycine
|
US20080305173A1
(en)
*
|
2001-07-31 |
2008-12-11 |
Beuford Arlie Bogue |
Amorphous drug beads
|
SK1012004A3
(sk)
*
|
2001-08-21 |
2005-04-01 |
Pfizer Products Inc. |
Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka
|
WO2003017981A1
(fr)
*
|
2001-08-29 |
2003-03-06 |
Ranbaxy Laboratories Limited |
Formulation a liberation controlee de clarithromycine ou de tinidazol
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
EP1541134A3
(fr)
*
|
2001-10-18 |
2007-06-06 |
Teva Pharmaceutical Industries Limited |
Compositions stabilisées de azithromycin
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
AU2002360717A1
(en)
*
|
2001-12-20 |
2003-07-09 |
Pharmacia Corporation |
Controlled release dosage form having improved drug release properties
|
PL371259A1
(en)
*
|
2001-12-21 |
2005-06-13 |
Pfizer Products Inc. |
Directly compressible formulations of azithromycin
|
NZ532063A
(en)
*
|
2001-12-21 |
2006-03-31 |
Pfizer Prod Inc |
Methods for wet granulating azithromycin
|
WO2003063838A1
(fr)
*
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Preparation d'azithromycine en granulat sec
|
BR0307515A
(pt)
*
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
|
JP4865989B2
(ja)
|
2002-02-01 |
2012-02-01 |
ベンド・リサーチ・インコーポレーテッド |
改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
|
KR100540035B1
(ko)
*
|
2002-02-01 |
2005-12-29 |
주식회사 태평양 |
다단계 경구 약물 방출 제어 시스템
|
US6682759B2
(en)
*
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
GB0203296D0
(en)
*
|
2002-02-12 |
2002-03-27 |
Glaxo Group Ltd |
Novel composition
|
CA2480824A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
ES2320438T7
(es)
|
2002-04-09 |
2013-02-14 |
Flamel Technologies |
Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
|
AU2003245504A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
GB0214013D0
(en)
*
|
2002-06-18 |
2002-07-31 |
Euro Celtique Sa |
Pharmaceutical product
|
US20040028737A1
(en)
*
|
2002-08-12 |
2004-02-12 |
Kopran Research Laboratories Limited |
Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
|
US8980870B2
(en)
*
|
2002-09-24 |
2015-03-17 |
Boehringer Ingelheim International Gmbh |
Solid telmisartan pharmaceutical formulations
|
US20040062778A1
(en)
*
|
2002-09-26 |
2004-04-01 |
Adi Shefer |
Surface dissolution and/or bulk erosion controlled release compositions and devices
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
EP1558211A2
(fr)
*
|
2002-10-30 |
2005-08-03 |
Pharmacia Corporation |
Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
|
US7351430B2
(en)
*
|
2002-11-06 |
2008-04-01 |
Uluru Inc. |
Shape-retentive hydrogel particle aggregates and their uses
|
US7811605B2
(en)
*
|
2002-11-06 |
2010-10-12 |
Uluru Inc. |
Method of formation of shape-retentive aggregates of gel particles and their uses
|
US7670627B2
(en)
*
|
2002-12-09 |
2010-03-02 |
Salvona Ip Llc |
pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
EP2402010A1
(fr)
|
2002-12-16 |
2012-01-04 |
Kissei Pharmaceutical Co., Ltd. |
Médicament solide pour administration orale
|
WO2004062577A2
(fr)
*
|
2003-01-03 |
2004-07-29 |
Shire Laboratories Inc. |
Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
|
FR2850577B1
(fr)
*
|
2003-02-03 |
2005-04-15 |
Ethypharm Sa |
Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
|
AU2004238253B2
(en)
*
|
2003-05-06 |
2011-01-27 |
Nostrum Pharmaceuticals, Inc. |
Controlled release formulation of erythromycin derivatives
|
US7063862B2
(en)
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
US7476403B2
(en)
*
|
2003-06-16 |
2009-01-13 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
US20050013835A1
(en)
*
|
2003-07-15 |
2005-01-20 |
Pfizer Inc. |
Stable non-dihydrate azithromycin oral suspensions
|
WO2005009368A2
(fr)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, utilisation et formulation correspondantes
|
WO2005009365A2
(fr)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, son utilisation et sa formulation
|
CA2533358C
(fr)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, utilisation et formulation associees
|
JP2005041838A
(ja)
*
|
2003-07-24 |
2005-02-17 |
Matsumoto Shika Univ |
バイオフィルム除去剤
|
US20050025829A1
(en)
*
|
2003-07-29 |
2005-02-03 |
Kim Cherng-Ju |
Controlled drug release tablets
|
CL2004001884A1
(es)
*
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
EP1653925A1
(fr)
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Pastille robuste
|
AU2004264356B2
(en)
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
EP1658034A4
(fr)
|
2003-08-29 |
2011-06-22 |
Middlebrook Pharmaceuticals Inc |
Produit antibiotique, son utilisation et sa formulation
|
CA2538064C
(fr)
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotique, son utilisation et sa formulation
|
WO2005053651A1
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Compositions multiparticulaires a stabilite amelioree
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
WO2005053652A1
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
|
WO2005053655A1
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Procede de fabrication de formes multiparticulaires pharmaceutiques
|
AU2004294813A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005053639A2
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
|
WO2005053654A1
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Formes posologiques d'azithromycine a liberation controlee
|
CN1889933A
(zh)
*
|
2003-12-04 |
2007-01-03 |
辉瑞产品公司 |
由基于液体的工艺制备的阿奇霉素多颗粒剂型
|
US20040224019A1
(en)
*
|
2004-03-03 |
2004-11-11 |
Adi Shefer |
Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
|
US7468428B2
(en)
*
|
2004-03-17 |
2008-12-23 |
App Pharmaceuticals, Llc |
Lyophilized azithromycin formulation
|
US20060116336A1
(en)
*
|
2004-03-17 |
2006-06-01 |
American Pharmaceutical Partners, Inc. |
Lyophilized azithromycin formulation
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
WO2005120585A1
(fr)
*
|
2004-06-04 |
2005-12-22 |
Case Western Reserve University |
Micelles polymeres a fonction double
|
US20070224269A1
(en)
*
|
2004-06-10 |
2007-09-27 |
Rubino Orapin P |
Controlled Release Pharmaceutical Formulation
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
CA2572292A1
(fr)
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Comprime pour distribution par impulsion
|
EP2965751A1
(fr)
*
|
2004-10-08 |
2016-01-13 |
Forward Pharma A/S |
Compositions pharmaceutiques à libération contrôlée comportant un ester d´acide fumarique
|
JP2008524317A
(ja)
*
|
2004-12-21 |
2008-07-10 |
ファイザー・プロダクツ・インク |
腸溶コーティングされたアジスロマイシン多粒子
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US10071060B2
(en)
*
|
2005-07-08 |
2018-09-11 |
Bioventures, Llc |
Asymmetrically coated table
|
US8858993B2
(en)
*
|
2005-07-25 |
2014-10-14 |
Metrics, Inc. |
Coated tablet with zero-order or near zero-order release kinetics
|
EP1749519A1
(fr)
*
|
2005-08-05 |
2007-02-07 |
Schering Aktiengesellschaft |
Forme galénique à libération prolongée pH-indépendant pour les substances actives avec une solubilité pH-dépendante
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
CA2634830A1
(fr)
*
|
2005-12-27 |
2007-07-05 |
Labopharm Inc. |
Composition de microbilles a base de polymere degradable
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US20070191271A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
US20070243248A1
(en)
*
|
2006-04-14 |
2007-10-18 |
Cherukuri S Rao |
Rapidly disintegrating solid oral dosage form of liquid dispersions
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US20070281894A1
(en)
*
|
2006-06-05 |
2007-12-06 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted erythromycin analogs
|
US7713549B2
(en)
*
|
2006-06-30 |
2010-05-11 |
Board Of Trustees Of The University Of Arkansas |
Extended release perforated tablet
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US7910135B2
(en)
*
|
2006-10-13 |
2011-03-22 |
Uluru Inc. |
Hydrogel wound dressing and biomaterials formed in situ and their uses
|
US20110052688A1
(en)
*
|
2006-11-21 |
2011-03-03 |
San-Laung Chow |
Solid dispersion composition
|
US11116728B2
(en)
|
2006-11-30 |
2021-09-14 |
Bend Research, Inc. |
Multiparticulates of spray-coated drug and polymer on a meltable core
|
EP2091519B1
(fr)
*
|
2006-11-30 |
2015-06-24 |
Bend Research, Inc |
Médicament enduit par vaporisation et polymère multiparticulaires sur un noyau pouvant fondre
|
CN100441196C
(zh)
*
|
2006-12-15 |
2008-12-10 |
北京化工大学 |
一种制备微粉化阿奇霉素的方法
|
US8895061B2
(en)
*
|
2007-03-02 |
2014-11-25 |
Meda Pharmaceuticals Inc. |
Compositions comprising carisoprodol and methods of use thereof
|
US20080228268A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Uluru, Inc. |
Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
|
BRPI0700969A
(pt)
*
|
2007-03-22 |
2008-11-04 |
Ouro Fino Participacoes E Empr |
composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
|
US7850453B2
(en)
*
|
2007-08-08 |
2010-12-14 |
Coll Partners Ltd. |
Reshapable device for fixation at a dental site
|
US8124123B2
(en)
*
|
2007-09-05 |
2012-02-28 |
Dow Pharmaceutical Sciences, Inc. |
Controlled release azithromycin solid dosages forms
|
CA2699169A1
(fr)
|
2007-09-11 |
2009-04-16 |
Mondobiotech Laboratories Ag |
Utilisation d'un peptide en tant qu'agent therapeutique
|
KR20100059862A
(ko)
|
2007-09-11 |
2010-06-04 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드의 용도
|
WO2009033797A2
(fr)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Utilisation d'un peptide en tant qu'agent thérapeutique
|
US20100204152A1
(en)
|
2007-09-11 |
2010-08-12 |
Dorian Bevec |
Use of gluten exorphin c : as a therapeutic agent
|
WO2009043461A1
(fr)
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Utilisation d'un peptide défensine hnp-1, seul ou en combinaison avec un neuropeptide af, en tant qu'agent thérapeutique
|
KR20100061676A
(ko)
|
2007-09-11 |
2010-06-08 |
몬도바이오테크 래보래토리즈 아게 |
녹농균 감염 치료에서 치료제로서의 멜라닌세포-자극 호르몬 방출-저해 인자의 용도
|
JP5385282B2
(ja)
|
2007-09-11 |
2014-01-08 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
治療剤としての血小板フィブリノーゲン受容体ヘキサペプチドアンタゴニストおよびα−エンドルフィンの使用
|
EP2197462A2
(fr)
|
2007-09-11 |
2010-06-23 |
Mondobiotech Laboratories AG |
Utilisation d'un peptide du recepteur de il-1, seule ou en combinaison avec un ester d-ala-gln-octadecyl, en tant qu'agent thérapeutique
|
WO2009033786A2
(fr)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Utilisation d'un peptide en tant qu'agent thérapeutique
|
US8383152B2
(en)
|
2008-01-25 |
2013-02-26 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
DE102008022520A1
(de)
*
|
2008-05-07 |
2009-11-12 |
Bayer Animal Health Gmbh |
Feste Arzneimittelformulierung mit verzögerter Freisetzung
|
HUE030803T2
(en)
|
2008-05-09 |
2017-06-28 |
Gruenenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
|
EP2198859A1
(fr)
*
|
2008-12-17 |
2010-06-23 |
Losan Pharma GmbH |
Composition pharmaceutique à revêtement par fusion avec libération
|
CA2766172C
(fr)
|
2009-07-22 |
2017-09-12 |
Lutz Barnscheid |
Forme galenique inviolable stabilisee a l'oxydation
|
CA2765971C
(fr)
|
2009-07-22 |
2017-08-22 |
Gruenenthal Gmbh |
Forme galenique extrudee a chaud a liberation controlee
|
US8795727B2
(en)
|
2009-11-09 |
2014-08-05 |
Spotlight Technology Partners Llc |
Fragmented hydrogels
|
WO2011057131A1
(fr)
|
2009-11-09 |
2011-05-12 |
Spotlight Technology Partners Llc |
Hydrogels à base de polysaccharide
|
EP2547322A2
(fr)
|
2010-03-15 |
2013-01-23 |
Ulrich Dietz |
Utilisation d'acides nitrocarboxyliques pour le traitement, le diagnostic et la prophylaxie de motifs de cicatrisation agressifs
|
WO2011125075A2
(fr)
|
2010-04-08 |
2011-10-13 |
Fdc Limited |
Nouveau système d'administration à rétention gastrique de macrolides
|
JP5933553B2
(ja)
|
2010-09-02 |
2016-06-15 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
アニオン性ポリマーを含む不正使用抵抗性剤形
|
BR112013005194A2
(pt)
|
2010-09-02 |
2016-05-03 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação compreendendo sal inorgânico
|
CA2823628A1
(fr)
|
2011-01-05 |
2012-07-12 |
Hospira, Inc. |
Sechage par atomisation de la vancomycine
|
EP2736497B1
(fr)
|
2011-07-29 |
2017-08-23 |
Grünenthal GmbH |
Comprimé multiparticulaire inviolable fournissant une libération immédiate de médicament
|
PE20141638A1
(es)
|
2011-07-29 |
2014-11-22 |
Gruenenthal Chemie |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
US9976171B2
(en)
*
|
2011-08-08 |
2018-05-22 |
Allergan Pharmaceuticals International Limited |
Method for dissolution testing of solid compositions containing digestive enzymes
|
US10799460B2
(en)
|
2011-09-07 |
2020-10-13 |
Roland SAUR-BROSCH |
Formulation for the controlled release of one or several substances in the digestive tract of a mammal
|
US10653631B2
(en)
|
2011-09-07 |
2020-05-19 |
Roland SAUR-BROSCH |
Optimal colon targeting technology
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013088274A1
(fr)
|
2011-12-14 |
2013-06-20 |
Wockhardt Limited |
Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
|
US20130172271A1
(en)
*
|
2012-01-04 |
2013-07-04 |
Cynthia Fragale |
Pharmaceutical Spray Drying
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
RU2498805C1
(ru)
*
|
2012-07-23 |
2013-11-20 |
Открытое акционерное общество "Биосинтез" |
Твердая лекарственная форма азитромицина
|
US20150202161A1
(en)
*
|
2012-08-20 |
2015-07-23 |
O-Ray Pharma, Inc. |
Process for manufacturing drug delivery formulations
|
CN103860515A
(zh)
*
|
2012-12-10 |
2014-06-18 |
中国科学院上海药物研究所 |
阿奇霉素渗透泵控释片及其制备方法
|
CN104043104B
(zh)
|
2013-03-15 |
2018-07-10 |
浙江创新生物有限公司 |
含盐酸万古霉素的喷雾干粉及其工业化制备方法
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
CN104177457A
(zh)
*
|
2013-05-23 |
2014-12-03 |
长春海悦药业有限公司 |
一种阿奇霉素药物原料及其制剂和用途
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
WO2014191397A1
(fr)
|
2013-05-29 |
2014-12-04 |
Grünenthal GmbH |
Forme pharmaceutique inviolable contenant une ou plusieurs particules
|
EP3878445A3
(fr)
|
2013-06-05 |
2021-10-27 |
Synchroneuron Inc. |
Formulations d'acamprosate, leurs procédés d'utilisation et combinaisons les comprenant
|
CN105682643B
(zh)
|
2013-07-12 |
2019-12-13 |
格吕伦塔尔有限公司 |
含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
|
US9668844B2
(en)
|
2013-11-06 |
2017-06-06 |
Colldent Y.A Ltd |
Device for fixation at a dental site
|
MX371372B
(es)
|
2013-11-26 |
2020-01-28 |
Gruenenthal Gmbh |
Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
|
US20150320690A1
(en)
|
2014-05-12 |
2015-11-12 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
WO2015181059A1
(fr)
|
2014-05-26 |
2015-12-03 |
Grünenthal GmbH |
Microparticules protégées contre une libération massive dans l'éthanol
|
MX2017013637A
(es)
|
2015-04-24 |
2018-03-08 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
|
AU2016274949B2
(en)
*
|
2015-06-10 |
2021-07-15 |
Dechra Veterinary Products, Llc |
Injectable antibiotic formulations and use thereof
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
WO2018190621A1
(fr)
*
|
2017-04-10 |
2018-10-18 |
성균관대학교 산학협력단 |
Préparation à libération prolongée comprenant une couche de rétention gastrique poreuse, et son procédé de préparation
|
GB201904757D0
(en)
*
|
2019-04-04 |
2019-05-22 |
Biorelevant Com Ltd |
Biorelevant composition
|
WO2021070121A1
(fr)
|
2019-10-11 |
2021-04-15 |
Anatara Lifesciences Limited |
Composition de santé gastro-intestinale
|
CN112326838A
(zh)
*
|
2020-11-10 |
2021-02-05 |
湖北省宏源药业科技股份有限公司 |
一种改善阿奇霉素胶囊溶出曲线的测定方法
|
CN113116859B
(zh)
*
|
2021-04-12 |
2022-08-30 |
海南普利制药股份有限公司 |
阿奇霉素丸芯包衣制剂
|
CN113985783B
(zh)
*
|
2021-10-29 |
2022-09-02 |
中山东菱威力电器有限公司 |
一种冰激淋料浆有无检测电路
|